Direkt zum Inhalt
Merck

P2900000

Prednison

European Pharmacopoeia (EP) Reference Standard

Synonym(e):

1,4-Pregnadien-17α,21-diol-3,11,20-trion, 1-Cortison, 17α,21-Dihydroxy-1,4-pregnadien-3,11,20-trion, Dehydrocortison

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise


About This Item

Empirische Formel (Hill-System):
C21H26O5
CAS-Nummer:
Molekulargewicht:
358.43
Beilstein:
2065301
MDL-Nummer:
UNSPSC-Code:
41116107
PubChem Substanz-ID:
NACRES:
NA.24

Qualität

pharmaceutical primary standard

API-Familie

prednisone

Hersteller/Markenname

EDQM

mp (Schmelzpunkt)

236-238 °C (lit.)

Anwendung(en)

pharmaceutical (small molecule)

Format

neat

Lagertemp.

2-8°C

SMILES String

O=C1C=C[C@@]2(C)C(CC[C@]([C@@](CC[C@@]3(C(CO)=O)O)([H])[C@]3(C)C4)([H])[C@]2([H])C4=O)=C1

InChI

1S/C21H26O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h5,7,9,14-15,18,22,26H,3-4,6,8,10-11H2,1-2H3/t14-,15-,18+,19-,20-,21-/m0/s1

InChIKey

XOFYZVNMUHMLCC-ZPOLXVRWSA-N

Angaben zum Gen

human ... NR3C1(2908)

Suchen Sie nach ähnlichen Produkten? Aufrufen Leitfaden zum Produktvergleich

Allgemeine Beschreibung

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Anwendung

Prednisone EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Verpackung

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Sonstige Hinweise

Sales restrictions may apply.

Piktogramme

Health hazard

Signalwort

Warning

H-Sätze

P-Sätze

Gefahreneinstufungen

STOT RE 2

Lagerklassenschlüssel

11 - Combustible Solids

WGK

WGK 3

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable


Choose from one of the most recent versions:

Analysenzertifikate (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Kundensupport

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Kunden haben sich ebenfalls angesehen

Karim Fizazi et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33(7), 723-731 (2015-01-28)
Orteronel (TAK-700) is an investigational, nonsteroidal, reversible, selective 17,20-lyase inhibitor. This study examined orteronel in patients with metastatic castration-resistant prostate cancer that progressed after docetaxel therapy. In our study, 1,099 men were randomly assigned in a 2:1 schedule to receive
Fred Saad et al.
The Lancet. Oncology, 16(3), 338-348 (2015-02-24)
Orteronel is an investigational, partially selective inhibitor of CYP 17,20-lyase in the androgen signalling pathway, a validated therapeutic target for metastatic castration-resistant prostate cancer. We assessed orteronel in chemotherapy-naive patients with metastatic castration-resistant prostate cancer. In this phase 3, double-blind
Lindsay Sonstein et al.
The American journal of medicine, 127(11), 1097-1104 (2014-06-15)
Clinical practice guidelines recommend 40-60 mg of prednisone equivalent for 10-14 days for patients with acute exacerbations of chronic obstructive pulmonary disease (COPD). However, the amount of corticosteroid prescribed varies widely in clinical practice. Using the electronic health record, we
Charles J Ryan et al.
The Lancet. Oncology, 16(2), 152-160 (2015-01-21)
Abiraterone acetate plus prednisone significantly improved radiographic progression-free survival compared with placebo plus prednisone in men with chemotherapy-naive castration-resistant prostate cancer at the interim analyses of the COU-AA-302 trial. Here, we present the prespecified final analysis of the trial, assessing
Maxime Touzot et al.
Transplantation, 99(1), 63-68 (2014-07-17)
Donor-specific antibodies (DSA) are considered as reliable biomarkers for antibody-mediated rejection (ABMR) diagnosis. However, it is unclear whether DSA monitoring is necessary and could predict graft outcome after antirejection treatment. We analyzed 28 non-sensitized kidney transplant patients with ABMR associated

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.